Structure via PubChem · Public domain (PubChem)
tivozanib
Sign in to saveAlso known as VEGFR tyrosine kinase inhibitor IV
Tivozanib, sold under the brand name Fotivda, is a medication used for the treatment of advanced renal cell carcinoma (kidney cancer). It is an oral VEGF receptor tyrosine kinase inhibitor.
Key facts
- Drug.image
- Tivozanib.svg
- Drug.image_class
- skin-invert-image
- Drug.tradename
- Fotivda
- Drug.MedlinePlus
- a621018
- Drug.licence_EU
- yes
- Drug.DailyMedID
- Tivozanib
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- L01
- Drug.ATC_suffix
- EK03
- Drug.legal_UK
- POM
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.protein_bound
- >99%
- Drug.elimination_half life
- 4.5–5.1 days
- Drug.excretion
- 79% feces, 12% urine
- Drug.CAS_number
- 475108-18-0
- Drug.PubChem
- 9911830
- Drug.IUPHAR_ligand
- 6058
via Wikipedia infobox
Chemical data
- Formula
- C22H19ClN4O5
- Molecular weight
- 454.9 g/mol
- IUPAC name
- 1-[2-chloro-4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-3-(5-methyl-1,2-oxazol-3-yl)urea
- SMILES
- CC1=CC(=NO1)NC(=O)NC2=C(C=C(C=C2)OC3=C4C=C(C(=CC4=NC=C3)OC)OC)Cl
- InChIKey
- SPMVMDHWKHCIDT-UHFFFAOYSA-N
- XLogP
- 4
- Polar surface area
- 108 Ų
- H-bond donors
- 2
- H-bond acceptors
- 7
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2017
- Admin. routes
- oral
- Indications
- neoplasm, hepatocellular carcinoma, renal cell carcinoma, non-small cell lung carcinoma
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 454.104
- Has use
- medication
Show 5 more facts
- medical condition treated
- renal cell carcinoma
- chemical formula
- C₂₂H₁₉ClN₄O₅
- canonical SMILES
- CC1=CC(=NO1)NC(=O)NC2=C(C=C(C=C2)OC3=C4C=C(C(=CC4=NC=C3)OC)OC)Cl
- isomeric SMILES
- CC1=C/C(=N\C(=O)Nc2ccc(cc2Cl)Oc3ccnc4c3cc(c(c4)OC)OC)/NO1
- subject has role
- protein kinase inhibitors
Sources (2)
via Wikidata · CC0
~6 min read
Encyclopedic overview
14 sectionsContents
- Medical uses
- Contraindications
- Adverse effects
- Interactions
- Pharmacology
- Mechanism of action
- Pharmacokinetics
- Chemistry
- History
- Clinical trials
- Society and culture
- Legal status
- References
- External links
Tivozanib, sold under the brand name Fotivda, is a medication used for the treatment of advanced renal cell carcinoma (kidney cancer). It is an oral VEGF receptor tyrosine kinase inhibitor.
The most common side effects include fatigue (tiredness), hypertension (high blood pressure), diarrhea, decreased appetite, nausea, dysphonia (voice changes), hypothyroidism, cough, and stomatitis.
Excerpted from Wikipedia’s “tivozanib” article, available under the CC BY-SA 4.0 licence.